In 1981, the United States became the first country to identify HIV/AIDS as a distinct condition. Since then, hundreds of thousands of people have become infected, and more than 500,000 have died from the HIV/AIDS virus. It’s a race to arms, as facilities throughout the world conduct studies to combat the virus. NanoViricides Inc. (OTCBB: NNVC) is one such company. Today the company announced that its anti-HIV drug candidates have demonstrated significant therapeutic efficacy in recent preliminary animal studies at a Bio-Safety Level 3 Laboratory facility in Boston, Mass.
The studies were conducted by Dr. Krishna Menon, PhD, VMD, MRCS, a world-renowned figure in preclinical and toxicological studies of innovative therapeutics. In the press release, the company said it anticipates releasing more information on further studies. NanoViricides is now working toward the protocol for a follow up anti-HIV study to be conducted at a major United States government research facility.
“Dr. Menon has indicated to us that the results of the study validate the company’s HivCide-I as a potential treatment for HIV/AIDS,” Eugene Seymour, MD, MPH, CEO of NanoViricides stated in the press release. “Over the next several weeks, we expect to release additional study data.”
Let us hear your thoughts below: